MRNA
Moderna, Inc.Thesis. MRNA at $79.77 sits 40% above the $47.58 consensus target after a 70% one-month FDA-vote melt-up, yet Q1 2026 revenue fell to $389M with a negative gross margin and a -$1.34B net loss. The $3.9B net cash cushion and improving loss trajectory keep this from being an outright short, but 18% short-float and 14x P/S on shrinking revenue make current levels a distribution zone, not an entry.
Scoreboard
At $79.77 the stock trades 6.8% off its $85.60 52-week high and a remarkable 258% above its $22.28 low — position-in-range 0.91, deep in nosebleed territory. The $31.7B market cap ($27.7B EV) capitalizes a business generating ~$2.2B trailing revenue at negative margins, implying 14.2x sales. Consensus mean target of $47.58 sits 40% below spot, one of the widest price-to-target gaps in large-cap biotech.
QoQ Changes
Q1 2026 revenue was $389M, down 42% from Q4 2025's $676M and off a seasonally strong $1.0B in Q3 2025 — the respiratory franchise remains hostage to a collapsing COVID/RSV demand curve. Basic EPS of -$3.40 deteriorated sharply from -$2.11 QoQ, though it still beat the -$4.04 consensus by 15.8%.
Q1 gross profit swung to -$566M (a negative gross margin) as fixed manufacturing absorbed a thin revenue base; operating margin ran -131% and EBITDA margin -103% on a trailing basis. Margins are structurally underwater until either a new product ramps or the cost base is cut further.
Trailing FCF margin is essentially breakeven-negative at -0.9%, with FCF yield near zero — a sign the reported operating burn is being offset by working-capital and receivable timing rather than genuine cash generation. Sustained sub-$400M quarterly revenue would reaccelerate cash consumption.
The balance sheet is the bull case: $5.2B cash ($13.12/share) against just $1.3B debt leaves $3.9B net cash and a 2.41 current ratio. Debt/equity of 17.5% and a 2.24 quick ratio mean solvency is not the question — runway duration versus pipeline delivery is.
MRNA screens expensive on every revenue-based metric: 14.2x P/S, 12.5x EV/revenue, 4.27x P/B versus an $18.66 book value. Forward P/E is meaningless at -19.3x and EV/EBITDA is -12.1x — there is no earnings anchor, so the multiple is a pure option premium on the pipeline.
Headcount stands at ~4,700, already reflecting prior cost-reduction rounds, and management continues to prioritize the Merck-partnered intismeran (individualized cancer vaccine) and combination respiratory shots. The disclosed Arbutus settlement (~$179M payout, per news flow) removes a legacy IP overhang but is a cash outflow, not a catalyst.
Ownership & Insider Activity
SEC Form 4 data shows no open-market conviction buying — the only P/S-coded trade is CLO Klinger's June 4 open-market sale of 3,471 shares at $50 (-$173,550), with the remaining activity being option exercises (M) and tax-withholding (F) at $47-52 prints. Net insider flow is -$173,550, and management was disposing into the run at prices well below spot. With 18.1% of float short and a 10.94-day short ratio, the squeeze mechanics that drove the melt-up cut both ways — thin selling can spike it, but there is no insider signal validating the price.
Recent Insider Transactions
No recent insider transactions on file.
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-03-31 Q1 | $-3.40 | $-4.04 | +$0.64 | +15.85% |
| 2025-12-31 Q4 | $-2.11 | $-2.70 | +$0.59 | +21.72% |
| 2025-09-30 Q3 | $-0.51 | $-2.15 | +$1.64 | +76.27% |
| 2025-06-30 Q2 | $-2.13 | $-3.03 | +$0.90 | +29.60% |
MRNA beat consensus EPS in 4 of the last 4 quarters with an average +35.9% surprise, but the beats are 'less-bad-than-feared' on a deeply negative base, not evidence of earnings power — a -$3.40 print beating a -$4.04 estimate is still a $1.3B loss.
Surprise magnitude is narrowing hard — from +76.3% in Q3 2025 to +21.7%, then +15.8% in Q1 2026 — signaling analysts have recalibrated to the loss run-rate and the easy expectations beats are behind the stock.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 0 | 4 | 19 | 4 | 3 | |
| 2026-06 | 0 | 4 | 19 | 4 | 3 | |
| 2026-05 | 2 | 7 | 18 | 2 | 1 | |
| 2026-04 | 0 | 3 | 21 | 3 | 3 |
The composition deteriorated sharply between May and June: Strong Buy/Buy collapsed from 2/7 to 0/4 while Hold held at ~19 and Sell/Strong Sell firmed at 4/3. The Street de-rated conviction into strength even as it nudged targets (RBC $38→$45, BofA $34→$38, both non-Buy).
Rating momentum is bearish — bullish ratings bled out over the visible window while price ran higher, widening the fundamental-technical gap.
Seven Essential Metrics
EBITDA margin -103%, operating margin -131%, ROE -36.6% — every profitability line is deeply negative.
Q1 2026 revenue of $389M fell 42% QoQ and the respiratory franchise is in secular decline despite a headline +260% trailing revenue-growth artifact.
FCF margin -0.9% and FCF yield ~-0.06% — no organic cash generation, only a large existing cash balance.
$3.9B net cash, $1.3B total debt, 17.5% debt/equity — balance sheet is the clean part of the story.
Beta 0.94 understates event risk; 18.1% short float, 10.94-day short ratio and binary pipeline readouts make this a high-volatility name.
14.2x P/S, 12.5x EV/revenue, negative fwd P/E (-19.3x) and EV/EBITDA (-12.1x) on shrinking revenue — priced for pipeline success not yet delivered.
No dividend and no active buyback; share count ~397M stable, but ongoing SBC and option exercises are a mild dilutive drift.
Capital is being retained to fund R&D and manufacturing; zero yield.
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
BNTX BioNTech SE | ~10% | ~-25% | ~5% | Net cash | ~35x |
PFE Pfizer Inc. | ~35% | ~-10% | ~20% | ~2x | ~9x |
NVAX Novavax Inc. | ~-20% | ~-30% | negative | <1x | n/a |
VIR Vir Biotechnology | negative | ~-40% | negative | Net cash | n/a |
Against BNTX — the closest mRNA comparable — MRNA carries a richer sales multiple with a thinner, still-loss-making P&L and no meaningful FCF, while both share the post-pandemic revenue cliff. PFE offers the profitability and 9x P/E that MRNA lacks, framing Moderna as the high-beta, pre-earnings 'platform optionality' trade in the group. Versus struggling small-caps NVAX/VIR, MRNA's $3.9B net cash and oncology partnership give it superior staying power, but that does not justify 14x sales.
Business & Strategy
Revenue is still dominated by respiratory vaccines — Spikevax (COVID), mRESVIA (RSV) and newer mNEXSPIKE — with the mix now brutally seasonal and shrinking as pandemic-era demand normalizes. The strategic pivot is toward latent-virus (CMV), oncology (intismeran with Merck) and rare-disease programs, none of which are yet material to the top line.
Primary customers are government/public-health procurement bodies (BARDA, DARPA, Gates Foundation) and commercial payers across the US, EU and international markets.
Product sales of approved vaccines plus grant/collaboration revenue from Merck, Vertex, BARDA and DARPA. Future streams hinge on regulatory approvals in oncology and latent-virus vaccines converting the mRNA platform into a multi-product annuity.
Fixed vaccine manufacturing capacity and a large R&D pipeline are the dominant cost drivers, which is why sub-$400M revenue quarters produce negative gross margins.
Moderna's moat is a proprietary, industrialized mRNA platform with demonstrated speed-to-clinic and a deep 40+ program pipeline plus blue-chip partners (Merck, Vertex, OpenAI). The moat is real but unmonetized outside COVID/RSV, and BNTX contests the same technological ground.
Monetary-Policy Sensitivity
- Long-duration equity — value skewed to distant pipeline cash flows, discount-rate sensitive
- Improved biotech risk appetite and generalist flows into unprofitable growth
- Lower cost of capital extends the runway narrative on the cash burn
As a profitless, long-duration name, MRNA benefits mechanically from lower discount rates that lift the present value of far-out oncology and latent-virus optionality. The effect is second-order versus pipeline data, however — rate cuts amplify moves but do not set direction for this stock.
SWOT Analysis
- $3.9B net cash and $13.12/share cash cushion fund years of runway
- Validated, industrial-scale mRNA platform with proven regulatory execution
- Blue-chip partnerships: Merck (oncology), Vertex (rare disease), BARDA/DARPA
- 4/4 EPS beats show disciplined expectation management and cost control
- Negative gross, operating and EBITDA margins; -$1.34B Q1 net loss
- Revenue down 42% QoQ with a structurally shrinking respiratory franchise
- No FCF generation — FCF margin -0.9%, yield near zero
- Insider activity is net selling with zero open-market conviction buys
- Intismeran (individualized neoantigen therapy) Phase 3 readouts with Merck
- Latent-virus (CMV, EBV) and combination respiratory vaccine approvals
- Norovirus and expanded public-health/pandemic-preparedness contracts
- 18% short float creates asymmetric squeeze potential on positive data
- Consensus target implies ~40% downside — valuation air pocket
- Continued post-COVID demand erosion across the vaccine portfolio
- Binary clinical/regulatory risk in the pipeline
- US vaccine-policy and reimbursement headwinds; heightened Q2 scrutiny (BofA)
Catalysts & Event Risks
- Q3 2026Q2 2026 earnings
BofA flagged Moderna for increased Q2 scrutiny; revenue trajectory and 2026 guidance are the key swing factors after the melt-up.
- 2026-07-31Arbutus settlement payout
Approximately $179M owed to Arbutus removes a legacy IP overhang but is a cash outflow.
- Q3 2026Intismeran (INT) oncology data
Merck-partnered individualized cancer vaccine readouts are the primary long-term value driver and biggest binary catalyst.
- H2 2026Respiratory season / mNEXSPIKE uptake
Fall vaccination demand will determine whether the respiratory franchise stabilizes or re-rates lower.
- H2 2026Latent-virus (CMV) pipeline milestones
Progress in the CMV program is critical to the multi-product platform thesis beyond respiratory.
The Q2 print into a 40%-above-target price is the near-term risk event — a soft revenue line or cautious guide could puncture the squeeze. Longer term, intismeran data is the only catalyst large enough to justify current valuation, making this a binary rather than a fundamentals-supported hold.
Technical Analysis
The stock sits at 0.91 of its 52-week range, 6.8% off the $85.60 high after a parabolic 258% advance from $22.28. It trades far above the $53.71 50-day and $41.68 200-day averages — extended and mean-reversion-prone. The $53-54 zone (50-day) is first meaningful support; a failure there opens air down toward the $45-48 consensus target. Risk-reward is skewed negative: limited upside to prior highs against a wide gap to fair value, with insider selling and de-rating analyst conviction consistent with distribution.
Verdict
Macro context. Post-pandemic vaccine demand normalization and a hostile US vaccine-policy backdrop remain the dominant sector headwinds, even as easing rate expectations support long-duration, profitless biotech. Moderna's beta of 0.94 belies event-driven volatility that dwarfs broad-market sensitivity.
Moderna is a well-capitalized platform with genuine optionality, but at $79.77 the market has already paid for pipeline success that has not arrived — 14x sales on 42%-QoQ-declining revenue, deep losses, and a price 40% above consensus. The narrowing EPS surprises, de-rating analyst conviction, and net insider selling all point to a stock ahead of its fundamentals. We rate MRNA REDUCE with a $48 target; the $3.9B net cash floor argues against shorting, but this is a level to trim into strength, not accumulate.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 6:48:01 AM